Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: Results of two 52-week, Phase III, randomized, placebo-controlled trials (INPULSIS™)
Ulrich Costabel(Ruhrlandklinik), HR Collard(University of California, San Francisco), Vincent Cottin(Université Claude Bernard Lyon 1), Michèle Brun(Boehringer Ingelheim (France)), Luca Richeldi(Coral Reef Alliance), Ganesh Raghu(University of Washington), Yoshino Inoue(NHO Kinki Chuo Chest Medical Center), Moisés Selman(Instituto Nacional de Enfermedades Respiratorias), Arata Azuma(Nippon Medical School Hospital), Rozsa Schlenker‐Herceg(Boehringer Ingelheim (United States)), K.J. Brown(National Jewish Health), H. Taniguchi(Tosei General Hospital), Martin Kolb(McMaster University), DS Kim(Sungkyunkwan University), PW Noble(Cedars-Sinai Medical Center), RM du Bois(Imperial College London), Martin Girard(Victim Support), KR Flaherty(Michigan Medicine), Bernd Disse(Boehringer Ingelheim (Taiwan))
Cited by 32
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
|The Lancet|2011|2.1k
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2006|1.3k